Abstract
Genmab A/S will report first-quarter 2026 results on May 7, 2026 Post Market; the preview below summarizes the latest quarter’s performance, consensus for revenue, earnings and margins, and the most recent analyst viewpoints ahead of the print.Market Forecast
Based on the latest compiled figures, Genmab A/S is projected to deliver first-quarter revenue of 888.13 million US dollars, up 17.37% year over year, with estimated EBIT of 120.04 million US dollars and EPS of 0.18 per share, implying an EPS contraction of 23.33% year over year; margin forecasts were not formally guided, so they are omitted here. The main revenue driver remains royalties, which historically comprise the bulk of revenue and are expected to lead this quarter’s top line; the most promising incremental contributor is product sales and partnered milestones tied to late-stage programs, with the company-level revenue growth of 17.37% year over year indicating a higher-volume start to 2026.Last Quarter Review
In the previous quarter, Genmab A/S reported revenue of 1.06 billion US dollars, a gross profit margin of 92.34%, GAAP net profit attributable to shareholders of 31.00 million US dollars, a net profit margin of 2.93%, and EPS of 0.21 per share; on a year-over-year basis, revenue grew 14.88% while EPS declined 75.03%. Quarter on quarter, net profit swung sharply lower with a decline of 92.27%, reflecting heavier operating expense timing and lower-than-anticipated EBIT of 58.00 million US dollars, which was down 81.22% year over year. By revenue mix in the last reported period, royalties contributed approximately 882.24 million US dollars (about 83.39% of revenue), net product sales contributed about 113.19 million US dollars (10.70%), milestones contributed about 27.59 million US dollars (2.61%), collaboration revenue contributed about 19.91 million US dollars (1.88%), and reimbursement income contributed about 15.07 million US dollars (1.42%); segment-level year-over-year growth was not disclosed, but consolidated revenue increased 14.88% year over year.Current Quarter Outlook (with major analytical insights)
Main revenue engine: Royalties and partnered sales
Royalties remain the primary revenue engine and are expected to shape first-quarter performance, with the consolidated top-line estimate pointing to 888.13 million US dollars, up 17.37% year over year. Historically, royalties have represented more than four-fifths of revenue, and the composition in the last reported period implies a similar mix near term. The combination of royalty-bearing therapies already on market and continued global uptake should sustain the high gross margin profile, which was 92.34% last quarter, even if operating leverage varies by expense timing. A key focus into the print is whether royalty growth can offset a guided EPS downtick, given the estimate implies EPS of 0.18 per share, down 23.33% year over year. Should royalties expand in line with the total revenue trajectory, EBIT of 120.04 million US dollars would be consistent with a profitable, cash-generative quarter despite heavier investment in pipeline programs.Largest growth potential: Product sales and milestone catalysts
Outside royalties, product net sales and milestones represent the most tangible growth levers, supported by last quarter’s contribution of 113.19 million US dollars in product sales and 27.59 million US dollars in milestones. Given the forecast 17.37% year-over-year rise in total revenue, the setup suggests a constructive demand backdrop for the company’s commercial and partnered portfolio, with milestones flexing based on clinical and regulatory events. Analyst commentaries during the quarter pointed to growing confidence in late-stage programs, with an expanded Phase III design for petosemtamab in combination settings cited as a potential medium-term driver. Translating that into near-term numbers, even modest uplifts in product sales and milestone receipts would carry high incremental margins, supporting EBIT even as EPS is projected to be lower year over year due to expense phasing. Execution on developmental and collaboration triggers, particularly those recognized as revenue, is therefore a swing factor for quarterly variability and a potential source of upside to the top-line estimate.What may drive the stock this quarter: Revenue growth vs. EPS compression and program updates
The market will likely weigh the trade-off between robust revenue growth and EPS compression implied by the current quarter’s estimates. On revenue, the 17.37% year-over-year growth outlook is a clear positive; however, the forecast EPS of 0.18 per share, down 23.33% year over year, suggests the company is investing behind its pipeline and commercial capabilities, while EBIT is estimated at 120.04 million US dollars. For equity investors, confirmation of high gross margin stability, together with clarity on operating expense cadence, will be crucial in assessing sustainability of earnings power in subsequent quarters. Also in focus are updates on late-stage clinical programs, including those flagged by analysts as potential value creators; any incremental visibility on pivotal trial recruitment, label expansions with partners, or milestones tied to regulatory interactions could affect the revenue mix and near-term cash flows. Net-net, the stock reaction is likely to be most sensitive to the balance of reported revenue versus operating expense timing and any qualitative commentary on upcoming catalysts, given that last quarter’s net profit margin of 2.93% left room for improvement if operating costs normalize.Analyst Opinions
Sentiment among institutions during the period from January 1, 2026 to April 30, 2026 skewed decisively positive, with a clear majority of bullish views and no bearish opinions observed in the collected set. William Blair maintained a Buy rating on April 22, citing conviction supported by an expanded Phase III program for petosemtamab in combination with a leading PD-1 therapy and confidence in the late-stage pipeline. Wells Fargo reiterated its Buy rating in March and set a 40.00 US dollars price target, reflecting expectations for sustained top-line growth and a favorable risk-reward into 2026. Goldman Sachs upgraded Genmab A/S to Buy on April 22 and raised its price target to 30.50 US dollars from 24.50 US dollars, highlighting improving growth visibility. Taken together, the ratio of bullish to bearish opinions in the reviewed window is 3:0, indicating a predominant bullish stance.From a fundamental perspective, the prevailing bullish view is anchored in three observations visible ahead of the quarter. First, the revenue estimate of 888.13 million US dollars, up 17.37% year over year, suggests continued momentum in royalty-bearing products and a supportive backdrop for partnered contributions. Second, while the EPS estimate of 0.18 per share implies a 23.33% year-over-year decline, analysts interpret the compression as a planned investment cycle rather than a deterioration of the core business, particularly given the high gross margin profile evidenced by the last quarter’s 92.34%. Third, the pipeline narrative—underscored by the expansion of key late-stage trials—offers credible medium-term optionality that could translate into future milestones and, ultimately, additional recurring revenue streams.
The consensus bullish case therefore emphasizes top-line durability and strategic investment. Revenue growth is expected to outpace earnings in the near term as operating expenses support clinical advancement, but analysts point to the robustness of royalties and the pace of development as catalysts that can enhance shareholder value beyond the quarter. Heading into May 7, 2026, the buyside will likely benchmark actual revenue against the 888.13 million US dollars estimate and parse commentary on spend cadence; should revenue land near or above expectations with disciplined expense signals and constructive program updates, the dominant bullish thesis appears well supported.
Comments